TREATMENT OF CANCER WITH ALK1 ANTAGONISTS

摘要

Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.

主权项

1. A method for evaluating responsiveness of a subject to treatment with an activin receptor-like kinase 1 (ALK1) antagonist, the method comprising:
(a) determining a level of bone morphogenetic protein 9 (BMP9) and/or bone morphogenetic protein 10 (BMP10) in a sample obtained from the subject; and (b) comparing the level of BMP9 and/or BMP 10 determined in (a) to a reference level, wherein (i) if the level determined in (a) is higher than the reference level, the subject is identified as responsive to treatment with the ALK1 antagonist; or (ii) if the level determined in (a) is the same or lower than the reference level, the subject is identified as not responsive to treatment with the ALK1 antagonist.